Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.37 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.37 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15569955 | 0.86 | KDM4E (0.44) | ALDH1A1HTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL339590 | 0.84 | SMN1; SMN2 (0.41) | ALDH1A1MAPK1SRD5A2AOC3TXNRD1 | |
| Hydrochloric Acid SCHEMBL11259230 | 0.84 | KDM4E (0.43) | ALDH1A1HTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31353412 | 0.80 | KDM4E (0.42) | ALDH1A1MAPK1HTTNPC1RAB9A | |
| SCHEMBL7851584 | 0.80 | KDM4E (0.42) | ALDH1A1MAPK1HTTNPC1RAB9A | |
| SCHEMBL11131562 | 0.80 | MAPT (0.37) | ALDH1A1MAPK1SRD5A2AOC3TXNRD1 | |
| SCHEMBL9489186 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MAPK1SRD5A2AOC3TXNRD1 | |
| SCHEMBL10705275 | 0.79 | HPGD (0.43) | ALDH1A1AOC3RAB9ASMN1; SMN2HPGD | |
| SCHEMBL4493633 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MAPK1SRD5A2AOC3TXNRD1 | |
| SCHEMBL423788 | 0.79 | AOC3 (0.49) | ALDH1A1MAPK1SRD5A2AOC3TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399490-B2 | Insecticides | SYNGENTA CROP PROTECTION LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399490-B2 | Insecticides | SYNGENTA CROP PROTECTION LLC (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2167484-B1 | CONDENSED ANTHRANILAMIDE INSECTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20100273830-A1 | NOVEL INSECTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273830-A1 | NOVEL INSECTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2009010260-A2 | CONDENSED ANTHRANILAMIDE INSECTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| EP-1095021-B1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2003-09-17 | — | — | EP | disclosed |
| US-6593343-B2 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2003-07-15 | — | — | US | disclosed |
| EP-1073639-B1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| US-20020173520-A1 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2002-11-21 | — | — | US | disclosed |
| US-20020173519-A1 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2002-11-21 | — | — | US | disclosed |
| EP-1095021-A1 | QUINOLINE DERIVATIVES | Active Biotech AB (SE) | 2001-05-02 | — | — | EP | disclosed |
| EP-1073639-A1 | QUINOLINE DERIVATIVES | Active Biotech AB (SE) | 2001-02-07 | — | — | EP | disclosed |
| US-6133285-A | 1-METHYL-2-OXO-3-N-PHENYL-N-METHYLAMINOCARBONYL-4-HYDROXY-1,2 -DIHYDRO-QUINOLINES; AUTOIMMUNE DISEASE AND PATHOLOGICAL INFLAMMATION, E.G., ASTHMA, ATHEROSCLEROSIS, STROKE AND ALZHEIMER'S DISEASE AND, ESPECIALLY, MULTIPLE SCLEROSIS | ACTIVE BIOTECH AB (SE) | 2000-10-17 | — | — | US | disclosed |
| US-6077851-A | USED FOR TREATMENT OF DISEASES RESULTING FROM AUTOIMMUNITY SUCH AS MULTIPLE SCLEROSIS, INSULIN-DEPENDENT DIABETES MELLITUS, SYSTEMIC LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS, INFAMMATORY BOWEL DISEASE AND PSORIASIS; LAQUINIMOD AS NEW CHEMICAL ENTITY | ACTIVE BIOTECH AB (SE) | 2000-06-20 | — | — | US | disclosed |
| WO-2000003991-A1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999055678-A1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 1999-11-04 | — | — | WO | disclosed |
| EP-0805812-A1 | BICYCLIC SUBSTITUTED HEXAHYDROBENZ(E)ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS | Abbott Laboratories (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022991-A1 | BICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173520-A1 | Quinoline derivatives | CYP4F3, IRF3, CXCR3 | ALDH1A1 3735/4885MAPK1 2380/4885SRD5A2 170/4885 |
| US-20100273830-A1 | NOVEL INSECTICIDES | NR5A2, NR2C2, NOX5 | ALDH1A1 1573/4885MAPK1 2012/4885SRD5A2 34/4885 |
| US-20020173519-A1 | Quinoline derivatives | CASP1, NFKBIA, IL1B | ALDH1A1 832/4885MAPK1 275/4885SRD5A2 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.